Our top pick for
Building a portfolio
Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
Jazz Pharmaceuticals plc is a biotechnology business based in the US. Jazz Pharmaceuticals shares (JAZZ) are listed on the NASDAQ and all prices are listed in US Dollars. Jazz Pharmaceuticals employs 1,940 staff and has a trailing 12-month revenue of around 0.00.
|Latest market close||$129.10|
|52-week range||$130.55 - $189.00|
|50-day moving average||$140.62|
|200-day moving average||$164.72|
|Wall St. target price||$207.82|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$0.69|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-09-14)||-4.33%|
|1 month (2021-08-20)||-3.30%|
|3 months (2021-06-22)||-27.19%|
|6 months (2021-03-22)||-24.32%|
|1 year (2020-09-21)||-7.11%|
|2 years (2019-09-20)||-0.09%|
|3 years (2018-09-21)||163.78|
|5 years (2016-09-21)||0.23%|
Valuing Jazz Pharmaceuticals stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Jazz Pharmaceuticals's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Jazz Pharmaceuticals's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 194x. In other words, Jazz Pharmaceuticals shares trade at around 194x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
Jazz Pharmaceuticals's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 4.9772. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Jazz Pharmaceuticals's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Jazz Pharmaceuticals's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $1.1 billion.
The EBITDA is a measure of a Jazz Pharmaceuticals's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||$2.6 billion|
|Operating margin TTM||27.11%|
|Gross profit TTM||$2.2 billion|
|Return on assets TTM||4.62%|
|Return on equity TTM||1.1%|
|Market capitalisation||$8.2 billion|
TTM: trailing 12 months
There are currently 3.7 million Jazz Pharmaceuticals shares held short by investors – that's known as Jazz Pharmaceuticals's "short interest". This figure is 12.8% down from 4.3 million last month.
There are a few different ways that this level of interest in shorting Jazz Pharmaceuticals shares can be evaluated.
Jazz Pharmaceuticals's "short interest ratio" (SIR) is the quantity of Jazz Pharmaceuticals shares currently shorted divided by the average quantity of Jazz Pharmaceuticals shares traded daily (recently around 841329.93197279). Jazz Pharmaceuticals's SIR currently stands at 4.41. In other words for every 100,000 Jazz Pharmaceuticals shares traded daily on the market, roughly 4410 shares are currently held short.
However Jazz Pharmaceuticals's short interest can also be evaluated against the total number of Jazz Pharmaceuticals shares, or, against the total number of tradable Jazz Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Jazz Pharmaceuticals's short interest could be expressed as 0.06% of the outstanding shares (for every 100,000 Jazz Pharmaceuticals shares in existence, roughly 60 shares are currently held short) or 0.0623% of the tradable shares (for every 100,000 tradable Jazz Pharmaceuticals shares, roughly 62 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Jazz Pharmaceuticals.
Find out more about how you can short Jazz Pharmaceuticals stock.
Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like Jazz Pharmaceuticals.
When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.
Total ESG risk: 31.66
Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and Jazz Pharmaceuticals's overall score of 31.66 (as at 12/31/2018) is nothing to write home about – landing it in it in the 51st percentile of companies rated in the same sector.
ESG scores are increasingly used to estimate the level of risk a company like Jazz Pharmaceuticals is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).
Environmental score: 4.18/100
Jazz Pharmaceuticals's environmental score of 4.18 puts it squarely in the 8th percentile of companies rated in the same sector. This could suggest that Jazz Pharmaceuticals is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.
Social score: 24.74/100
Jazz Pharmaceuticals's social score of 24.74 puts it squarely in the 8th percentile of companies rated in the same sector. This could suggest that Jazz Pharmaceuticals is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.
Governance score: 13.74/100
Jazz Pharmaceuticals's governance score puts it squarely in the 8th percentile of companies rated in the same sector. That could suggest that Jazz Pharmaceuticals is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.
Controversy score: 1/5
ESG scores also evaluate any incidences of controversy that a company has been involved in. Jazz Pharmaceuticals scored a 1 out of 5 for controversy – the highest score possible, reflecting that Jazz Pharmaceuticals has managed to keep its nose clean.
|Total ESG score||31.66|
|Total ESG percentile||51.04|
|Environmental score percentile||8|
|Social score percentile||8|
|Governance score percentile||8|
|Level of controversy||1|
We're not expecting Jazz Pharmaceuticals to pay a dividend over the next 12 months.
Over the last 12 months, Jazz Pharmaceuticals's shares have ranged in value from as little as $130.55 up to $189. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Jazz Pharmaceuticals's is 0.9722. This would suggest that Jazz Pharmaceuticals's shares are less volatile than average (for this exchange).
Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of neuroscience, including sleep medicine and movement disorders; and in oncology, including hematologic and solid tumors. Its lead marketed products include Xyrem, an oral solution for the treatment of cataplexy and excessive daytime sleepiness (EDS) in narcolepsy patients seven years of age and older; Sunosi for the treatment of EDS in patients with narcolepsy and obstructive sleep apnea; Erwinaze to treat acute lymphoblastic leukemia; Defitelio for the treatment of adult and pediatric patients with hepatic veno-occlusive disease; Vyxeos liposome for injection, a product for the treatment of adults with newly-diagnosed therapy-related acute myeloid leukemia; and Zepzelca for the treatment of adult patients with metastatic small cell lung cancer. The company also offers Xywav, an oxybate product candidate, to treat EDS and cataplexy with narcolepsy and idiopathic hypersomnia; JZP-324, a low sodium oxybate formulation with the potential to provide a clinically meaningful option for narcolepsy patients; JZP-385, a T-type calcium channel modulator, for the treatment of essential tremor; JZP-458, a recombinant Erwinia asparaginase, for use as a component of a multi-agent chemotherapeutic regimen in the treatment of pediatric and adult patients; and JZP-150 for treatment of post-traumatic stress disorder. Jazz Pharmaceuticals plc has licensing and collaboration agreements with ImmunoGen, Inc. ; Codiak BioSciences, Inc. ; Pfenex, Inc.
Everything we know about the MiNK Therapeutics IPO, plus information on how to buy in.
Everything we know about the Wetouch Technology IPO, plus information on how to buy in.
Everything we know about the Life Time Group Holdings IPO, plus information on how to buy in.
Everything we know about the Slinger Bag IPO, plus information on how to buy in.
Everything we know about the NSTS Bancorp IPO, plus information on how to buy in.
Everything we know about the Volcon IPO, plus information on how to buy in.
Everything we know about the Thomas James Homes IPO, plus information on how to buy in.
Everything we know about the FGI Industries IPO, plus information on how to buy in.
Everything we know about the Zhong Yang Financial Group IPO, plus information on how to buy in.
Everything we know about the Exscientia Ltd IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.